The EASL Congress 2024 brings together over 7,000 professionals, including clinicians, researchers, allied health professionals, patient representatives, and industry professionals.
This event includes four interactive days with hands-on learning sessions led by world-class faculty, presenting a fantastic opportunity for the liver community to share research, network, and engage with leading hepatology experts.
Poster
| Ravidasvir in combination with sofosbuvir for 12 or 24 weeks achieved high sustained virological response rates in genotype 3 chronic hepatitis C without or with compensated liver cirrhosis Tan S S*, Menétrey C, Ribeiro I, Salvadori N, Yerly S, Ngo-Giang-Huong N, Diap G |
